Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Pipeline
  • AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist
  • Pipeline

AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist

BioSpace

The lineup at the Alzheimer's Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurode

Neuroscience

Read full story

pharminent July 10, 2026 (Last updated: July 10, 2026)

BioSpace

The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurode

Neuroscience

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar
Next: Hengrui-Kailera Oral GLP-1 Phase 3 Data Lands From China

Related Stories

  • Pipeline

Roche scraps two Ionis-partnered Huntington’s drugs

pharminent July 9, 2026
  • Pipeline

Keenova eyes Xiaflex as first drug for plantar fibromatosis

pharminent July 9, 2026
  • Pipeline

AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project

pharminent July 1, 2026

You May Have Missed

  • News

Roche Scraps Two Ionis-Partnered Huntington’s Studies After Tominersen Failure

pharminent July 10, 2026
  • News

Hengrui-Kailera Oral GLP-1 Phase 3 Data Lands From China

pharminent July 10, 2026
  • Pipeline

AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist

pharminent July 10, 2026
  • M&A / Deals

Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

pharminent July 10, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.